Skip to content
Sign in
Health · Asia Pacific

Australian-led trial finds mRNA vaccine combination lowers melanoma risks

An Australian-led phase three trial found that a personalised mRNA vaccine combined with post-surgery immunotherapy significantly reduced melanoma recurrence and death risk. Researchers described the findings as a major advance in cancer treatment.

AI-assisted synthesis · Based on 2 independent reports from 4 outletsHow it's made

View timeline · 9 entries
4 outletsLatest reporting 3 min read
Coverage: Center OnlyL 0 · C 4 · R 0
Updat3 graphic: Australia
Updat3 graphic · Map data: Natural Earth Natural Earth (public domain)

What happened

Key facts

  • An Australian-led phase three trial tested a personalised mRNA cancer vaccine alongside a standard post-surgery immunotherapy drug.
  • The trial found the combination significantly reduced the risk of melanoma recurrence and death.
  • Professor Georgina Long and the late Richard Scolyer were named Australian of the Year in 2024.
  • The work was announced on October 23, 2026.
  • Principal investigator Professor Georgina Long called the findings a “very, very big leap forward.”

The brief

An Australian-led trial of the mRNA vaccine intismeran found a 42 per cent reduction in the risk of melanoma recurrence when the vaccine was added to treatment after surgery. The study included more than 1,100 people with high-risk melanoma that had been surgically removed, according to nine.com.au and The West Australian.

The two reports describe the result with different levels of detail. Nine.com.au says the risk of recurrence two years later fell by 42 per cent after intismeran was added to treatment following surgery.

The West Australian reports Moderna and Merck’s announcement that the vaccine reduced the risk of recurrence or death by 42 per cent when used with Keytruda, compared with immunotherapy alone. The reports therefore do not describe precisely the same measured outcome or comparison. Nine.com.au says intismeran was made specifically for each trial participant.

Both reports identify it as an mRNA cancer vaccine. The study was funded by Moderna and Merck, according to nine.com.au; The West Australian also attributes the result announcement to those companies. Professor Georgina Long led the trial and served as its principal investigator, the reports say.

Long, whom The West Australian identifies as Australian of the Year alongside the late Richard Scolyer in 2024, called the findings a “very, very big leap forward.” The West Australian also reports her description of the potential clinical impact as profound and says she referred to results from a Phase 2 trial as lasting.

The trial’s scale and reported reduction make the findings relevant to people treated for high-risk melanoma, while the reports provide different descriptions of the endpoint: recurrence alone in one account and recurrence or death in the other. Neither report supplies a separate figure for deaths or a detailed breakdown of outcomes.

The West Australian quotes a statement that responsive manufacturing will be important in Australia, where someone is diagnosed with melanoma every 30 minutes. That report does not identify the speaker in the supplied excerpt, so the remark cannot be confidently assigned to Long or another named participant.

The findings concern a clinical trial, and the reports do not give a publication date for the study results or details of a regulatory decision. The reported outcome is a trial finding; the excerpts do not establish that intismeran is approved for general use.

Why it matters

  • For people with high-risk melanoma whose tumours have been removed, recurrence can mean facing further treatment and a greater risk of death; the reported reduction suggests a personalised vaccine may help prevent the cancer returning when added to pembrolizumab. If confirmed in further research, the approach could change care after surgery and support testing personalised mRNA vaccines against other cancers. The trial results do not yet establish whether the treatment improves survival or how widely it can be used.

What to watch next

  • Whether Moderna and Merck provide further detail on the different reported endpoints: recurrence alone or recurrence-or-death.
  • Whether further information specifies the trial’s comparison group and the treatment regimen used alongside intismeran.
  • Whether a regulatory decision on intismeran is reported.
  • Whether further results clarify how the individualized vaccine was produced for trial participants.

How it's being covered

Coverage analysisShow details
4 source articles · 4 unique outlets · 2 distinct reports
Outlet political mix: Center Only· 4 Center
Where the outlets are based: Asia 100%
Outlet political mix
Center Only
Left
Center
Right
0 outlets
4 outlets
0 outlets
The marker shows coverage balance: each unique outlet counts once.
Geography
Where the outlets covering this story are based.
4 unique outletsDominant coverage: Asia
Coverage imbalance
  • Coverage is currently concentrated among Center-rated outlets (4 of 4 rated sources); comparatively few Left or Right-rated outlets have published on the event.
  • Coverage is currently concentrated among outlets based in Asia (4 of 4 geographically-identified sources).
How we measure coverage

How outlets' accounts compare

3 framing differences · 2 uncorroborated claims · 2 information gaps
The reports repeat the same account with different emphasis; its central claims are not independently confirmed in the reporting Updat3 read.Compared across 2 reports whose article text Updat3 read.
Framing / emphasis differences
Sources emphasise different angles, actors or consequences of the same reporting.
  • Nine.com.au emphasizes an individualized vaccine added to treatment after surgery and reports a 42 per cent reduction in recurrence risk two years later.
  • The West Australian frames the finding as a company announcement and specifies Keytruda, recurrence or death as the outcome, and immunotherapy alone as the comparison.
  • The reports describe different outcome measures and comparisons: recurrence two years later in the nine.com.au account, versus recurrence or death compared with immunotherapy alone in The West Australian.
Updat3: These are differences of emphasis, not disputes about what is reported. They do not show that the reported claims are true.
One-sided or uncorroborated claims
Claims that come from one party or one source family and are not independently corroborated.
  • Professor Georgina Long called the findings a “very, very big leap forward.”
  • The West Australian quotes an unidentified speaker saying responsive manufacturing will matter in Australia, where someone is diagnosed with melanoma every 30 minutes.
Updat3: Not independently corroborated yet — treat as a claim, not an established fact.
Not established by the reporting
Information the available reporting does not contain or confirm. This is a gap, not a disagreement.
  • Neither report supplies the trial’s publication details, a full account of its design, or a separate count of recurrence events and deaths.
  • Neither report provides information about regulatory review or approval of intismeran.
Updat3: Updat3 cannot conclude anything about this from the current sources.

Timeline

Developments from this story's sources, dated background we compiled and fact-checked, and our earlier coverage. Each row says which.
  1. The underlying research predates the COVID-19 pandemic: laboratory demonstrations in 1989 showed that manufactured mRNA could be used to make cells produce a chosen protein.
    Background · from our historical context
  2. Katalin Karikó and Drew Weissman published research on nucleoside-modified mRNA that reduced innate immune activation.
    Background · compiled and fact-checked by Updat3
  3. The FDA approved pembrolizumab for advanced melanoma.
    Background · compiled and fact-checked by Updat3
  4. Moderna and Merck announced a collaboration to develop personalized cancer vaccines using mRNA.
    Background · compiled and fact-checked by Updat3
  5. The FDA approved pembrolizumab after surgery for certain high-risk melanoma patients.
    Background · compiled and fact-checked by Updat3
  6. Regulators authorized or approved mRNA COVID-19 vaccines from Pfizer-BioNTech and Moderna.
    Background · compiled and fact-checked by Updat3
  7. In December 2022, Moderna and Merck reported initial findings from KEYNOTE-942, a phase 2b study of the personalized vaccine with pembrolizumab after surgery for high-risk melanoma.
    Background · from our historical context
  8. The companies announced the phase 3 INTerpath-001 trial in February 2023.
    Background · from our historical context
  9. The trial’s principal investigator was Professor Georgina Long, named Australian of the Year alongside the late Richard Scolyer in 2024.
    Reported in this story's sourcesSource:thewest.com.aunine.com.au

How we got here

Pembrolizumab, marketed as Keytruda, is a checkpoint inhibitor that blocks the PD-1 protein, which can restrain immune-cell activity. The US Food and Drug Administration first approved pembrolizumab for advanced melanoma in 2014 and later approved its use after surgery for certain high-risk patients, in 2019. Messenger RNA carries instructions that cells use to make proteins.

The underlying research predates the COVID-19 pandemic: laboratory demonstrations in 1989 showed that manufactured mRNA could be used to make cells produce a chosen protein. Intismeran, previously called mRNA-4157, is a personalized mRNA cancer vaccine developed by Moderna with Merck.

Original sources

4 articles from 4 outlets

Every story links to the reporting it was built from. How we choose sources

Spotted a factual error, a broken link or a misleading summary? Tell us.